Structure Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Structure Therapeutics

05/05/2025 22:26

Structure Therapeutics Inc GPCR.OQ GPCR.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Structure Therapeutics Inc is for a loss of 23 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Structure Therapeutics Inc is $79.50​, above​ its last closing price of $27.55. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.23
-0.22
-0.69
Missed
-208.3
Sep. 30 2024
-0.17
-0.19
-0.60
Missed
-222.8
Jun. 30 2024
-0.22
-0.23
-0.54
Missed
-137.9​
Mar. 31 2024
-0.21
-0.21
-0.57
Missed
-170.5
​​Dec. 31 2023
-0.21
-0.21
-0.66
Missed
-217.3
Sep. 30 2023
-0.37
-0.29
-0.62
Missed
-112.9​
Jun. 30 2023
-0.20
-0.28
-0.60
Missed
-116.3
Mar. 31 2023
-0.41
-0.41
-0.25
Beat
39.5

This summary was machine generated May 5 at 21:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)